These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 26174908)

  • 1. Body mass index as a prognostic factor in Asian patients treated with chemoimmunotherapy for diffuse large B cell lymphoma, not otherwise specified.
    Hwang HS; Yoon DH; Suh C; Huh J
    Ann Hematol; 2015 Oct; 94(10):1655-65. PubMed ID: 26174908
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Visceral adipose tissue is prognostic for survival of diffuse large B cell lymphoma treated with frontline R-CHOP.
    Shin DY; Kim A; Byun BH; Moon H; Kim S; Ko YJ; Kim MJ; Lee HR; Kang HJ; Na II; Park S; Lee SS; Yang SH
    Ann Hematol; 2016 Feb; 95(3):409-16. PubMed ID: 26658607
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma.
    Weiss L; Melchardt T; Habringer S; Boekstegers A; Hufnagl C; Neureiter D; Hopfinger G; Greil R; Egle A
    Ann Oncol; 2014 Jan; 25(1):171-6. PubMed ID: 24299961
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anthropometrics and prognosis in diffuse large B-cell lymphoma: a multicentre study of 653 patients.
    Bendtsen MD; Munksgaard PS; Severinsen MT; Bekric E; Brieghel C; Nielsen KB; Brown PN; Dybkaer K; Johnsen HE; Bøgsted M; El-Galaly TC
    Eur J Haematol; 2017 Apr; 98(4):355-362. PubMed ID: 27893172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of the prognostic value of BMI and the difference in its impact according to age and sex in DLBCL patients.
    Kanemasa Y; Shimoyama T; Sasaki Y; Tamura M; Sawada T; Omuro Y; Hishima T; Maeda Y
    Hematol Oncol; 2018 Feb; 36(1):76-83. PubMed ID: 28449294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Prognostic Impact of Body Mass Index in Patients with Diffuse Large B-Cell Lymphoma: A Meta-Analysis.
    Wang Z; Luo S; Zhao X
    Nutr Cancer; 2021; 73(11-12):2336-2346. PubMed ID: 32964748
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Overweight/obese status associates with favorable outcome in patients with metastatic nasopharyngeal carcinoma: a 10-year retrospective study.
    Li W; Shen LJ; Chen T; Sun XQ; Zhang Y; Wu M; Shu WH; Chen C; Pan CC; Xia YF; Wu PH
    Chin J Cancer; 2016 Aug; 35(1):75. PubMed ID: 27507261
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Obesity and survival in advanced non-small cell lung cancer patients treated with chemotherapy, immunotherapy, or chemoimmunotherapy: a multicenter cohort study.
    Nie W; Lu J; Qian J; Wang SY; Cheng L; Zheng L; Tao GY; Zhang XY; Chu TQ; Han BH; Zhong H
    BMC Med; 2024 Oct; 22(1):463. PubMed ID: 39402614
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evaluation of different staging systems and prognostic analysis of 110 primary gastrointestinal diffuse large B cell lymphoma].
    Mao L; Wang X; Wang CY; Xia B; Ning QY; Yang HL; Yu Y; Zhang YZ
    Zhonghua Yi Xue Za Zhi; 2019 Jun; 99(24):1853-1858. PubMed ID: 31269579
    [No Abstract]   [Full Text] [Related]  

  • 10. Increased body mass index is associated with improved survival in United States veterans with diffuse large B-cell lymphoma.
    Carson KR; Bartlett NL; McDonald JR; Luo S; Zeringue A; Liu J; Fu Q; Chang SH; Colditz GA
    J Clin Oncol; 2012 Sep; 30(26):3217-22. PubMed ID: 22649138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic significance of serum beta-2 microglobulin in patients with diffuse large B-cell lymphoma in the rituximab era.
    Seo S; Hong JY; Yoon S; Yoo C; Park JH; Lee JB; Park CS; Huh J; Lee Y; Kim KW; Ryu JS; Kim SJ; Kim WS; Yoon DH; Suh C
    Oncotarget; 2016 Nov; 7(47):76934-76943. PubMed ID: 27764777
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of body mass index on survival of patients with stage I non-small cell lung cancer.
    Xie HJ; Zhang X; Wei ZQ; Long H; Rong TH; Su XD
    Chin J Cancer; 2017 Jan; 36(1):7. PubMed ID: 28069048
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High Red Cell Distribution Width is an Adverse Predictive and Prognostic Factor in Patients With Diffuse Large B-Cell Lymphoma Treated With Chemoimmunotherapy.
    Beltran BE; Paredes S; Castro D; Cotrina E; Sotomayor EM; Castillo JJ
    Clin Lymphoma Myeloma Leuk; 2019 Sep; 19(9):e551-e557. PubMed ID: 31320254
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era.
    Chen H; Qin Y; Yang J; Liu P; He X; Zhou S; Zhang C; Gui L; Yang S; Shi Y
    Leuk Res; 2021 Nov; 110():106715. PubMed ID: 34598076
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic nutritional index, a novel biomarker which predicts worse prognosis in diffuse large B cell lymphoma.
    He J; Yin H; Xia Y; Wu JZ; Liang JH; Zhu HY; Fan L; Li JY; Wang L; Xu W
    Leuk Res; 2021 Nov; 110():106664. PubMed ID: 34271293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients.
    Gouveia GR; Ferreira SC; Siqueira SAC; de Pádua Covas Lage LA; Hallack Neto AE; de Oliveira Costa R; Pereira J
    BMC Cancer; 2020 Oct; 20(1):1041. PubMed ID: 33121489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COO and MYC/BCL2 status do not predict outcome among patients with stage I/II DLBCL: a retrospective multicenter study.
    Barraclough A; Alzahrani M; Ettrup MS; Bishton M; van Vliet C; Farinha P; Gould C; Birch S; Sehn LH; Sovani V; Ward MS; Augustson B; Biccler J; Connors JM; Scott DW; Gandhi MK; Savage KJ; El-Galaly T; Villa D; Cheah CY
    Blood Adv; 2019 Jul; 3(13):2013-2021. PubMed ID: 31285189
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The Enhanced International Prognostic Index for Diffuse Large B-cell Lymphoma.
    Yang Y; Wang L; Ma Y; Han T; Huang M
    Am J Med Sci; 2017 May; 353(5):459-465. PubMed ID: 28502332
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab.
    Oki Y; Yamamoto K; Kato H; Kuwatsuka Y; Taji H; Kagami Y; Morishima Y
    Eur J Haematol; 2008 Dec; 81(6):448-53. PubMed ID: 18691256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.